Conference Speakers

Dr. Keipert has over 30 years of industry experience that includes eight years of CRO experience in his current employment with Parexel International, five years of consulting in pharmaceutical drug development of both perfluorochemical (PFC) emulsions and hemoglobin-based oxygen carriers (HBOCs) as temporary blood substitutes or oxygen therapeutics, and 21 years employed in Biotech working for Sangart Inc. as VP, Clinical for development of two HBOCs for use in surgery, trauma and Sickle Cell disease, and for Alliance Pharmaceutical Corp. as Program Director overseeing development of a PFC-based oxygen therapeutic (perflubron emulsion). Prior post-doctoral experience includes nine years of basic and applied laboratory research focused on various HBOC formulations in both university and US military research facilities.

Dr. Keipert’s broad industry expertise encompasses preclinical and clinical drug development, project leadership, regulatory submissions (FDA & EMA), nonclinical research in animal models of oxygen transport, hemodilution and hemorrhagic shock resuscitation, product development, strategic planning, technical/medical writing/presentations, and scientific publication. His in-depth understanding of clinical research derives from hands-on experience designing, managing, and executing more than 20 clinical trials globally (Phase I to III). His work on both HBOCs and PFC emulsions for use as a temporary red cell substitute or as an oxygen therapeutic agent has generated more than 160 publications including 64 papers, 92 abstracts, and 6 book chapters. Dr. Keipert’s therapeutic area experience covers Cardiovascular, Ophthalmology, Endocrinology (Diabetes), Pulmonology, Critical Care (Trauma), Hematology (Sickle Cell disease), Transfusion medicine, and Surgery (cardiopulmonary bypass and joint arthroplasty).